Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539591 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
A Phase 2 study of Malignant Melanoma, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT00539591 is a Phase 2 study of Malignant Melanoma that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 29 participants, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00539591, a Phase 2 study of Malignant Melanoma, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous melanoma.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Peginterferon alfa-2b
- DRUG Recombinant interferon alfa-2b
Study Locations (3)
California
- Rady Children's Hospital - San Diego
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- The Children's Cancer Hospital at UT M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-05-09 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539591
The ClinicalTrials.gov registry entry for NCT00539591 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (84% lower). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT00539591 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT00539591 about?
NCT00539591 is a clinical study titled "Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma". The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous melanoma.
What is the current status of trial NCT00539591?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2008-05-09. Estimated completion is 2026-05.
What conditions does trial NCT00539591 study?
This clinical trial studies the following conditions: Malignant Melanoma.
What interventions are being tested in trial NCT00539591?
The interventions under investigation include: Temozolomide (DRUG), Peginterferon alfa-2b (DRUG), Recombinant interferon alfa-2b (DRUG).
Who is sponsoring clinical trial NCT00539591?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00539591 being conducted?
This trial has 3 study locations across California, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
RECRUITING · Phase 2
-
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
COMPLETED · Phase 2
-
Phase II Trial of Allovectin-7® for Metastatic Melanoma
COMPLETED · Phase 2
-
GM-CSF as Adjuvant Therapy of Melanoma
COMPLETED · Phase 2
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.